P616 IBD reference and biosimilar adalimumab CroSS over study (iBaSS): design considerations and methodology
ECCO'20 Vienna
2020
P617 Mesenchymal stromal cells of bone marrow reduce the risk of postoperative recurrence of Crohn’s disease
ECCO'20 Vienna
2020
P618 Post-operative Crohn’s disease patients undergoing colonoscopy require significantly more analgesia and sedation compared with a non-IBD population
ECCO'20 Vienna
2020
P619 Efficacy of zinc acetate hydrate administration for zinc deficiency in patients with inflammatory bowel disease: a multi-centre retrospective study
ECCO'20 Vienna
2020
P620 Maintenance of clinical remission with SB5 biosimilar after switch from adalimumab originator: Real-life experience of a tertiary referral centre
ECCO'20 Vienna
2020
P621 Physician preferences for biologics (originator vs. biosimilar) for the treatment of ulcerative colitis in France, Germany and the UK
ECCO'20 Vienna
2020
P622 Recovery of nutrient deficiency as a predictor of remission in inflammatory bowel diseases
ECCO'20 Vienna
2020
P623 Cumulative incidence of infliximab use after a first flare of acute severe colitis
ECCO'20 Vienna
2020
P624 Maintenance of remission after treatment with Exclusive Enteral Nutrition and Azathioprine in paediatric patients with Crohn’s disease
ECCO'20 Vienna
2020
P625 Kinetics and outcomes of transmural healing in patients with Crohn’s disease treated with anti-TNF therapy
ECCO'20 Vienna
2020
P626 Patients with IBD seek extra supportive care: insights from Israeli social media networks
ECCO'20 Vienna
2020
P628 Histological remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission
ECCO'20 Vienna
2020
P629 Long-term effectiveness and safety of ustekinumab (UST) in patients with active Crohn’s disease (CD) in real life: Interim analysis of the SUSTAIN study
ECCO'20 Vienna
2020
P631 Predictors of vedolizumab treatment persistence in bio-naïve ulcerative colitis patients
ECCO'20 Vienna
2020